Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer
| Autor: | M González-Cao, Rafael Fábregas, Ignacio Rodríguez, F Fargas, M. Cusido, B. Úbeda, Sonia Baulies, C. Ara, Francisco Tresserra |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Multivariate analysis Receptor ErbB-2 medicine.medical_treatment Antineoplastic Agents Breast Neoplasms Pathological response Breast cancer Breast cancer chemotherapy Internal medicine Humans Medicine skin and connective tissue diseases neoplasms Pathological Retrospective Studies Chemotherapy business.industry Obstetrics and Gynecology Middle Aged medicine.disease Neoadjuvant Therapy Treatment Outcome Receptors Estrogen Hormone receptor T-stage Female Receptors Progesterone business |
| Zdroj: | Journal of Obstetrics and Gynaecology. 35:485-489 |
| ISSN: | 1364-6893 0144-3615 |
| DOI: | 10.3109/01443615.2014.968113 |
| Popis: | We report our experience in neoadjuvant breast cancer chemotherapy in a single centre between 2000 and 2011. We looked for predictive factors for response to neoadjuvant chemotherapy in the present study. A total of 110 consecutive breast cancer patients were treated with neoadjuvant chemotherapy in our centre. Pathological response was achieved in 24 HR+/HER2- (38.7%), 25 HER2+ (67.6%) and five triple-negative (45.5%) (p = 0.02) patients. No statistically significant differences were found in pathological tumour response according to T stage. The multivariate analysis revealed tumour subtype was the only associated factor for pathological response, with HER2 + tumours the best responders, OR 3.9 (1.5-9.9): 5-year DFS was 40% HER2+/no response; 78% HER2+/response; 65% HR+/HER2-/no response; 82% HR+/HER2-/response; 25% triple-negative/no response and 100% triple-negative/response. HR and HER2 status were the only prognostic factors for pathological response. pCR was correlated with survival in all tumour subtypes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|